34 results about "Basal ganglia" patented technology

The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalamus.

The invention provides a transcranial magnetic therapeutic instrument for computer diseases, comprising a field effect cap which can be worn on head, field effect cap internally being distributed with electrodes and at least one electromagnet; the instrument further comprises an electroencephalographic simulative generator, and the electroencephalographic simulative generator is respectively connected with the electromagnet and the electrodes via conducting wires. In the invention, nerve cell nucleus of intracephalic basal ganglia part can be self-excited by a stereoscopic superposition alternating magnetic field transcranially magnetically formed at intracephalic deep part and a weak induced current formed at a specific part of intracephalic deep part; and the transcranial magnetic effect is strengthened when the nerve cell nucleus transcranially pass through basal ganglia part. The invention is not an interventional therapy but can achieve the functions of stimulating and recoveringneurotransmitters of nerve cell nucleus of intracephalic basal ganglia part such as autocrine dopamine, and is applied to encephalopathic therapy such as Parkinson, encephalatrophy, epileptics and gork; the effects exceed that of a brain pacemaker, thereby overcoming the disadvantages of pharmacotherapy and surgical therapy; and the therapeutic instrument can be used in hospital, and is more applied to treatment of patients at home.

The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.

The invention provides a deep brain stimulation FPGA experimental platform of a basal ganglia and thalamencephalon network for the parkinson's disease. The experimental platform comprises an FPGA development board and an upper computer, which are connected with each other; the FPGA development board is used for realizing a basal ganglia and thalamencephalonneuron network model and a deep brain stimulation controller; the upper computer is used for designing an upper computer software interface and being communicated with the FPGA development board. The experimental platform has the benefits that as an animal-free experiment means of a biological neural network, and on the basis of the high-speed computation FPGA neuron network, the experimental platform realizes the modeling of the neuron network of a complex parkinson's disease focus area, and the neuron network model can be consistent with real biological neuron on a time scale. The platform provides a visual research platform, closer to the real neuron network, for researching the discharging mechanism of the parkinson's disease and the abnormal discharging mode of the basal ganglia and thalamencephalonneuron network controlled by deep brain stimulation, and has a significant practical value in researching the treatment of the parkinson's disease.

The invention provides a trabscranial magnetoelectric depression therapeutic apparatus, comprising a pair of earphones, a beam connected between the earphones, at least a magnet, at least a pair of electrodes and an internal circuit; wherein, the earphones and the electrodes are connected with the internal circuit. The technical proposal is as follows: trabscranial magnetoelectricity and audio signals directly act on heads and auditory systems of human; stereo superposition electric field formed in certain parts of brain by trabscranial magnet can ensure the parts to generate weak induced current so as to self stimulate the parts to secrete dopamine and restore the function of self secreting neurotransmitter such as dopamine by the parts; the trabscranial magnet directly stimulates neutral clusters of basal ganglia of thalamus, thus strengthening the effects of the trabscranial magnet; the audio signals with special rhythm act on the auditory systems of human, which can promote human to enter into meditation and tempt secretion of the neurotransmitter such as dopamine in the brain, thus further strengthening the effects of the trabscranial magnet. The trabscranial magnetoelectricity and audio signals integrate three effects into one, supplement and complement each other and promote each other, and the therapeutic effect on depression and insomnia is unreachable for any single function.

The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and / or basal ganglia, is provided.

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, R1 and R2 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.